Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference

On February 7, 2023 Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, reported that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 4:20 PM ET (Press release, Outlook Therapeutics, FEB 7, 2023, View Source [SID1234626924]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.

Miravo Healthcare™ Announces Filing of Special Meeting Materials in respect of Arrangement with Searchlight Pharma Inc.

On February 7, 2023 Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) ("Miravo" or the "Company") reported that it has filed and is in the process of mailing the management information circular (the "Circular") and related materials in connection with the special meeting (the "Meeting") of its shareholders (the "Shareholders") to be held virtually on March 7, 2023 (Press release, Nuvo Pharmaceuticals, FEB 7, 2023, View Source [SID1234626923]). The Meeting has been called for Shareholders to consider and, if deemed advisable, to pass a special resolution (the "Arrangement Resolution") approving the previously announced plan of arrangement (the "Arrangement") involving the Company and Searchlight Pharma Inc. (the "Purchaser"), pursuant to which the Purchaser has agreed to acquire all of the issued and outstanding common shares of the Company (the "Company Shares") in exchange for cash consideration of $1.35 per Company Share (the "Consideration"), subject to the terms and conditions of an arrangement agreement dated December 22, 2022 (the "Arrangement Agreement"). The Meeting is to be held in accordance with an interim order from the Ontario Superior Court of Justice (Commercial List) (the "Court") obtained on February 6, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The board of directors of the Company (the "Board"), after receiving legal and financial advice, and based upon, among other things, its receipt of a fairness opinion from Bloom Burton Securities Inc., has unanimously determined that the Arrangement is in the best interests of the Company (taking into account the interests of all affected stakeholders) and the Consideration to be received by Shareholders pursuant to the Arrangement is fair to Shareholders. Accordingly, the Board recommends that Shareholders vote FOR the Arrangement Resolution at the Meeting.

Each of the directors and executive officers of the Company who are Shareholders, as well as one of the Company’s significant Shareholders, Red Oak Partners, LLC, who collectively own or control, directly or indirectly, approximately 23.16% of the Company Shares, have entered into voting support agreements with the Purchaser to, among other things, vote their Company Shares in favour of the Arrangement.

Meeting and Circular

The Meeting is scheduled to be held as a virtual-only meeting conducted via live audio webcast at www.virtualshareholdermeeting.com/mrvsm2023 on March 7, 2023 at 9:00 a.m. (Toronto time). Shareholders of record as at the close of business on January 23, 2023 are entitled to receive notice of and vote at the Meeting.

Shareholders are encouraged to vote virtually at the Meeting or by proxy or voting instruction form. Proxies must be submitted no later than 9:00 a.m. (Toronto time) on March 3, 2023, or 48 hours (not including Saturdays, Sundays and holidays) prior to the commencement of any adjourned or postponed Meeting. Shareholders may also vote online during the Meeting as more particularly described in the Circular.

The Circular provides important information on the Arrangement and related matters, including the background to the Arrangement, the rationale for the recommendation made by the Board, voting procedures and how to virtually attend the Meeting. Shareholders are urged to read the Circular and its appendices carefully and in their entirety, and, if assistance is required, Shareholders are urged to consult their financial, legal, tax or other professional advisors. The Circular and the Arrangement Agreement are available on the Company’s profile on SEDAR at www.sedar.com.

In order to become effective, the Arrangement will require Court approval and must be approved by: (i) at least two-thirds of the votes cast by Shareholders, and (ii) a simple majority of the votes cast by Shareholders, excluding for this purpose votes attached to Company Shares held by persons described in items (a) through (d) of Section 8.1(2) of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transaction.

In addition to Court and Shareholder approval, the Arrangement is subject to, among other things, the satisfaction or waiver of certain closing conditions customary in transactions of this nature. Subject to the satisfaction of such conditions, the Arrangement is expected to close in the first quarter of 2023.

Kura Oncology to Participate in SVB Securities Global Biopharma Conference

On February 7, 2023 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported its participation in the virtual SVB Securities Global Biopharma Conference (Press release, Kura Oncology, FEB 7, 2023, View Source [SID1234626922]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 5:00 p.m. ET / 2:00 p.m. PT on February 14, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available following the event.

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

On February 7, 2023 Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, reported that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:40 p.m. Eastern time (Press release, Keros Therapeutics, FEB 7, 2023, View Source [SID1234626921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat presentation will be available at View Source and an archived replay will be accessible in the Investors section of the Keros website at View Source for up to 90 days following the conclusion of the event.

Innate Pharma to Participate in Upcoming Investor Conferences

On February 7, 2023 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that members of its senior management team are scheduled to participate in the following upcoming investor conferences (Press release, Innate Pharma, FEB 7, 2023, View Source [SID1234626920]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Securities Global Biopharma Conference
Event Date: February 14 – 16, 2023 (virtual)

Citi’s 2023 Virtual Oncology Leadership Summit
Event Date: February 22, 2023 (virtual)

H.C. Wainwright Cell Therapy Virtual Conference
Event Date: February 28, 2023 (virtual)